Rivastigmine patch ameliorates depression in Mild AD: Preliminary evidence from a 6-month open-label observational study

Gianfranco Spalletta, Walter Gianni, Franco Giubilei, Anna R. Casini, Giuseppe Sancesario, Carlo Caltagirone, Luca Cravello

Research output: Contribution to journalArticlepeer-review

Abstract

Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild AlzheimerÊs Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n=50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE frequency were evaluated with the Mini Mental State Examination, the CERAD Dysphoria scale and the modified DSM-IV criteria for MDE in AD. MDE frequency reduced significantly from the first diagnostic visit (100%) to the 6-month follow-up (62%). We also found a significant reduction in CERAD Dysphoria scores that decreased from 6.2±3.9 mean±standard deviation to 4.9±4.5 at the 6-month follow-up. In AD patients with MDE rivastigmine alone can have a positive impact on depressive phenomena. Thus, future controlled study are justified to definitively verify if rivastigmine alone may improve depression in AD.

Original languageEnglish
Pages (from-to)289-291
Number of pages3
JournalAlzheimer Disease and Associated Disorders
Volume27
Issue number3
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Alzheimer disease
  • depression
  • neuropsychiatric symptoms
  • rivastigmine

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Gerontology
  • Clinical Psychology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Rivastigmine patch ameliorates depression in Mild AD: Preliminary evidence from a 6-month open-label observational study'. Together they form a unique fingerprint.

Cite this